Frederick Locke

45PUBLICATIONS
317CO-AUTHORS
Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (45)

|Sep 30, 2026
IFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma.

|Sep 23, 2026
Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma.

|Sep 18, 2026
RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR-T Resistant Large B-cell Lymphomas.

|Jul 17, 2026
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

|May 11, 2026
Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

|Nov 13, 2025
Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.

Caron A Jacobson, Jason R Westin, David B Miklos

Pageof 8

Frequent Collaborators

18 joint publications

Michael Jain

10 joint publications

Olalekan Oluwole

9 joint publications

David B Miklos

8 joint publications

Taiga Nishihori